Nanopharmaceutics Announces Presentation of National Cancer Institute sponsored Phase I Study with Triapine at ESMO 2025
Phase I Study with Triapine + Lutetium Lu 177 Dotatate in patients with progressive well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) TRON Group Inc. (OTCMKTS:TGRP) ALACHUA, FL, UNITED STATES, September 10, 2025 / …